Study S001894

SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years

ClinicalTrials.gov record

Registration

Registration: NCT07845994
Acronym: SEMAFORCRANIO
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 50
Start: 2026-11
Primary completion: 2031-02
Lead sponsor: University Hospital, Angers
Conditions: Craniopharyngioma, Child
Interventions: DRUG:Semaglutide (Wegovy) weekly injection; DRUG:Placebo weekly Injection
Results posted: FALSE
Individual participant data sharing: UNDECIDED
Secondary identifiers: CTIS:2024-511114-20-00

Registered primary outcomes

Change in BMI SD score (according to french references) at 40 weeks [40 weeks]
Change in BMI SD score (according to french references) at 80 weeks [80 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.